MedMira's Multiplo Rapid Test to Be Used by Canadian Forces Health Services Group
HALIFAX, April 14 /CNW/ - MedMira Inc., ("MedMira") (TSXV: MIR) (NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that the Company's Multiplo rapid test for HIV and Hepatitis B and C will be used by the Canadian Forces Health Services Group (CFHS). The CFHS is the designated health care provider for Canada's military personnel, delivering medical and dental services at military installations across Canada and overseas.
CFHS personnel can use the Multiplo rapid test in cases of occupational exposures, medical surveillance programs, and routine medical checks. The Multiplo test also enables healthcare professionals to quickly screen patients and blood supply for HIV, Hepatitis B and C in the field. Built on MedMira's patented diagnostics technology platform, Multiplo takes less than three minutes and just a single drop of blood to provide a simultaneous diagnosis of the three diseases.
"We are very pleased that the Canadian Forces sees the value that Multiplo can add to the services provided by the CFHS Group to military personnel at home and abroad. We are confident that Multiplo will become a key tool and offer the CFHS Group flexibility and performance in a broad range of settings from laboratories to large scale screening programs to field hospitals in areas of conflict," said Hermes Chan, CEO, MedMira Inc. "It is an honor and a privilege to provide our military with a world class diagnostic technology."
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis of infectious diseases. MedMira diagnostics are sold under the Reveal®, MiraWell®, Multiplo™, and Miriad brands in global markets. MedMira's rapid HIV test is the only rapid HIV test in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, including statements regarding development of sales opportunities, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.For further information:
MedMira Contact: Andrea Young